<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>神经性疼痛市场报告 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/shenjingxingtengtongshichangbaogao/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 21 Dec 2021 03:06:17 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>神经性疼痛市场报告 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>全球神经性疼痛市场研究报告预测到2023年</title>
		<link>https://www.yuanzhezixun.com/quanqiushenjingxingtengtongshichangyanjiubao/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Mon, 29 Apr 2019 01:08:37 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Abbott Laboratories (U.S.)]]></category>
		<category><![CDATA[Astellas Pharma Inc. (Tokyo)]]></category>
		<category><![CDATA[AstraZeneca (U.K.)]]></category>
		<category><![CDATA[Baxter Healthcare Corporation (U.S.)]]></category>
		<category><![CDATA[Biogen Inc. (U.S.)]]></category>
		<category><![CDATA[Depomed Inc. (U.S.)]]></category>
		<category><![CDATA[Eli Lilly and Company (U.S.)]]></category>
		<category><![CDATA[GlaxoSmithKline Plc (U.K.)]]></category>
		<category><![CDATA[Neuropathic Pain]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Sanofi S.A. (France)]]></category>
		<category><![CDATA[三叉神经痛]]></category>
		<category><![CDATA[创伤后神经病]]></category>
		<category><![CDATA[包埋性神经病]]></category>
		<category><![CDATA[周围神经病]]></category>
		<category><![CDATA[带状疱疹后神经痛]]></category>
		<category><![CDATA[幻肢痛]]></category>
		<category><![CDATA[神经性疼痛]]></category>
		<category><![CDATA[神经性疼痛市场报告]]></category>
		<category><![CDATA[神经性疼痛市场预测]]></category>
		<category><![CDATA[神经性疼痛药物市场]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=19685</guid>

					<description><![CDATA[诸如引入疼痛管理中心等因素以及对仿制药的更高需求预计消除更高水平的疼痛会促进全球神经性疼痛市场的增长。预计全球神经性疼痛市场在2018-2023预测期间的复合年增长率将达到6.06％。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
